Alimera Sciences Inc (NASDAQ:ALIM) 2018 Q1 Sentiment Change

June 17, 2018 - By Maria Brooks

Alimera Sciences, Inc. (NASDAQ:ALIM) Logo

Sentiment for Alimera Sciences Inc (NASDAQ:ALIM)

Alimera Sciences Inc (NASDAQ:ALIM) institutional sentiment increased to 1.5 in 2018 Q1. Its up 0.50, from 1 in 2017Q4. The ratio increased, as 15 institutional investors increased or started new holdings, while 10 sold and reduced their equity positions in Alimera Sciences Inc. The institutional investors in our partner’s database now hold: 28.53 million shares, down from 28.68 million shares in 2017Q4. Also, the number of institutional investors holding Alimera Sciences Inc in their top 10 holdings was flat from 0 to 0 for the same number . Sold All: 4 Reduced: 6 Increased: 10 New Position: 5.

Alimera Sciences, Inc., a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. The company has market cap of $60.02 million. It focuses on diseases affecting the back of the eye or retina. It currently has negative earnings. The firm offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema , which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness.

The stock increased 2.01% or $0.0169 during the last trading session, reaching $0.8569. About 152,378 shares traded. Alimera Sciences, Inc. (NASDAQ:ALIM) has declined 46.58% since June 17, 2017 and is downtrending. It has underperformed by 59.15% the S&P500.

Jw Asset Management Llc holds 0.71% of its portfolio in Alimera Sciences, Inc. for 696,000 shares. Armistice Capital Llc owns 6.94 million shares or 0.55% of their US portfolio. Moreover, Venbio Select Advisor Llc has 0.31% invested in the company for 6.24 million shares. The California-based Acuta Capital Partners Llc has invested 0.16% in the stock. Knott David M, a New York-based fund reported 228,000 shares.

Since January 1, 0001, it had 2 insider buys, and 10 selling transactions for $280,303 activity.

Another recent and important Alimera Sciences, Inc. (NASDAQ:ALIM) news was published by which published an article titled: “The UK National Institute For Health And Care Excellence To Undertake A Partial Review Of The ILUVIEN …” on June 11, 2018.

Alimera Sciences, Inc. (NASDAQ:ALIM) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: